Search results for "Multiple drug resistance"

showing 10 items of 113 documents

2017

The 6-epimer of the plakortide H acid (1), along with the endoperoxides plakortide E (2), plakortin (3), and dihydroplakortin (4) have been isolated from a sample of the Caribbean sponge Plakortis halichondrioides. To perform a comparative study on the cytotoxicity towards the drug-sensitive leukemia CCRF-CEM cell line and its multi-drug resistant subline CEM/ADR5000, the acid of plakortin, namely plakortic acid (5), as well as the esters plakortide E methyl ester (6) and 6-epi-plakortide H (7) were synthesized by hydrolysis and Steglich esterification, respectively. The data obtained showed that the acids (1, 2, 5) exhibited potent cytotoxicity towards both cell lines, whereas the esters s…

biology010405 organic chemistryStereochemistryPharmaceutical Sciencemedicine.diseasebiology.organism_classification01 natural sciences0104 chemical sciencesMultiple drug resistance03 medical and health sciencesLeukemiaHydrolysisSponge0302 clinical medicineCell culture030220 oncology & carcinogenesisDrug DiscoverymedicineSteglich esterificationCytotoxicityPharmacology Toxicology and Pharmaceutics (miscellaneous)IC50Marine Drugs
researchProduct

Interactions between artemisinin derivatives and P-glycoprotein

2019

Abstract Background Artemisinin was isolated and identified in 1972, which was the starting point for a new era in antimalarial drug therapy. Furthermore, numerous studies have demonstrated that artemisinin and its derivatives exhibit considerable anticancer activity both in vitro, in vivo, and even in clinical Phase I/II trials. P-glycoprotein (P-gp) mediated multi-drug resistance (MDR) is one of the most serious causes of chemotherapy failure in cancer treatment. Interestingly, many artemisinin derivatives exhibit excellent ability to overcome P-gp mediated MDR and even show collateral sensitivity against MDR cancer cells. Furthermore, some artemisinin derivatives show P-gp-mediated MDR r…

ATP Binding Cassette Transporter Subfamily BPharmaceutical ScienceAntineoplastic AgentsPharmacology03 medical and health sciences0302 clinical medicineCombined treatmentIn vivoNeoplasmsparasitic diseasesDrug DiscoverymedicineHumansATP Binding Cassette Transporter Subfamily B Member 1Artemisinin030304 developmental biologyP-glycoproteinPharmacology0303 health sciencesbiologyChemistryArtemisininsDrug Resistance MultipleCancer treatmentMultiple drug resistanceComplementary and alternative medicine030220 oncology & carcinogenesisCancer cellbiology.proteinMolecular Medicinemedicine.drugPhytomedicine
researchProduct

Repurposing old drugs to fight multidrug resistant cancers.

2020

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approa…

0301 basic medicineVirtual screeningCancer ResearchDrug repurposingSettore BIO/11 - Biologia MolecolareAntineoplastic AgentsDrug resistanceBioinformatics03 medical and health sciencesClinical cancer trials; Drug repurposing; Multidrug resistant cancer; Pharmacophore modelling; Virtual screening0302 clinical medicineNeoplasmsDrug DiscoveryMedicineHumansPharmacology (medical)Computer SimulationRepurposingPharmacologyVirtual screeningDrug discoverybusiness.industryDrug RepositioningComputational BiologyDrug Resistance Multiple3. Good healthMultiple drug resistanceDrug repositioning030104 developmental biologyInfectious DiseasesOncologyDrug developmentDrug Resistance Neoplasm030220 oncology & carcinogenesisMultidrug resistant cancerPharmacophore modellingPharmacophorebusinessClinical cancer trialsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Predominance of the fimH30 Subclone Among Multidrug-Resistant Escherichia coli Strains Belonging to Sequence Type 131 in Italy

2013

GeneticsSettore MED/07 - Microbiologia E Microbiologia ClinicaST131 E. coli fimH30 sub-clone in ItalyBiologymedicine.disease_causeAnti-Bacterial AgentsMicrobiologyMultiple drug resistanceInfectious DiseasesType (biology)Drug Resistance Multiple BacterialCorrespondenceEscherichia colimedicineHumansImmunology and AllergyEscherichia coliEscherichia coli InfectionsFluoroquinolonesSequence (medicine)Journal of Infectious Diseases
researchProduct

Phenotypic and genotypic study on antibiotic resistance and pathogenic factors of Staphylococcus aureus isolates from small ruminant mastitis milk in…

2021

Staphyloccoccus aureus is the major cause of mastitis in small ruminants in the Mediterranean farms causing severe losses to dairy industry. Antibiotic treatment has been the most common approach to control these infections. Aim of this study was to investigate antimicrobial resistance (AMR), virulence factors and biofilm-related genes of 84 Sicilian strains of S. aureus isolated from sheep and goats milk during two different periods δT1 (2006-2009) and δT2 (2013-2015). Kirby Bauer method and Polymerase Chain Reaction (PCR) were utilized to monitor AMR and related genes (mecA, tetK, tetM, ermA, ermC). Moreover, toxin genes (tsst-1, sea-see, seg-sej, and sep) and biofilm genes (bap, ica, sas…

Staphylococcus aureusStaphylococcus aureus; Antimicrobial resistance; Virulence factors BiofilmVirulence factorsTetracyclineSulfamethoxazoleSCCmecBiofilmBiologyTP368-456medicine.disease_causemedicine.diseaseAntimicrobial resistanceFood processing and manufactureArticleMicrobiologyMastitisMultiple drug resistanceAntibiotic resistanceStaphylococcus aureusmedicineStaphylococcus aureuVancomycinFood Sciencemedicine.drugItalian Journal of Food Safety
researchProduct

Trends of extended-spectrum β-lactamase-producing Escherichia coli sequence type 131 and its H30 subclone in a French hospital over a 15-year period.

2016

International audience; Sequence type 131 (ST131) is a predominant lineage among extraintestinal pathogenic Escherichia coli. It plays a major role in the worldwide dissemination of E. coli producing extended-spectrum β-lactamases (ESBLs). Here we describe the long-term epidemiology of this clonal group in a French university hospital, where the incidence of ESBL-producing E. coli has increased from 0.018 case per 1000 patient-days in the year 2000 to 0.50 case per 1000 patient-days in 2014. The first of the 141 ST131 isolates was recovered in 2006, and the ST131 clonal group accounted for 18.1% of total ESBL-producing E. coli over the whole period (2000-2014). Subclonal typing showed that …

0301 basic medicineMESH : Escherichia coliMESH : Retrospective StudiesMESH : Multilocus Sequence TypingMESH: beta-LactamasesMESH : GenotypeMultidrug resistancemedicine.disease_causeHospitals UniversityMESH: Genotype[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyPharmacology (medical)MESH: IncidenceMESH: Genetic VariationEscherichia coli InfectionsComputingMilieux_MISCELLANEOUSCross InfectionMolecular EpidemiologyExtraintestinal Pathogenic Escherichia coliMESH: Escherichia coliIncidenceIncidence (epidemiology)MESH : beta-LactamasesGeneral MedicinePFGEMESH : IncidenceElectrophoresis Gel Pulsed-Field3. Good healthInfectious DiseasesMESH: Electrophoresis Gel Pulsed-FieldMESH: Multilocus Sequence Typing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMESH : Escherichia coli Infections[SDE]Environmental SciencesFranceMESH : Cross InfectionMicrobiology (medical)clone (Java method)Lineage (genetic)GenotypeMESH : Molecular Epidemiology030106 microbiologyBiologybeta-LactamasesMicrobiology03 medical and health sciencesExtended-spectrum β-lactamaseMESH : Genetic VariationEscherichia coliPulsed-field gel electrophoresismedicineHumansMESH: Molecular EpidemiologyTypingMESH : FranceEscherichia coliMESH : Hospitals UniversityRetrospective StudiesMESH : Electrophoresis Gel Pulsed-FieldMESH: Escherichia coli InfectionsMESH: Hospitals UniversityMESH: HumansMESH : HumansGenetic VariationMESH: Cross InfectionMESH: Retrospective Studiesbacterial infections and mycosesMultiple drug resistanceMESH: FranceESBLMultilocus Sequence Typing
researchProduct

Collateral Sensitivity in Drug-Resistant Tumor Cells

2013

Collateral sensitivity is a term for the hypersensitivity of otherwise drug-resistant cells. The selective killing of tumor cells by drugs exerting collateral sensitivity might be used as a novel treatment strategy. In this chapter, we give an overview on drug resistance phenotypes with known collateral sensitivities; furthermore, their molecular and cellular mechanisms were discussed to explain mediation of these hypersensitivities.

ChemotherapybiologyCollateralbusiness.industrymedicine.medical_treatmentTumor cellsDrug resistancePhenotypeMultiple drug resistancebiology.proteinmedicineCancer researchTreatment strategybusinessP-glycoprotein
researchProduct

Tumor Microenvironment And Epithelial Mesenchymal Transition As Targets To Overcome Tumor Multidrug Resistance

2020

It is well established that multifactorial drug resistance hinders successful cancer treatment. Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR). TME-induced factors secreted by cancer cells and cancer-associated fibroblasts (CAFs) create an inflammatory microenvironment by recruiting immune cells. CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) and inflammatory tumor associated macrophages (TAMs) are main immune cell types which further enhance chronic inflammation. Chronic inflammation nurtures tumor-initiating/cancer stem-like cells (CSCs), induces both EMT and MDR leading to tumor re…

0301 basic medicineCancer Researchmedicine.medical_treatmentMultidrug resistanceTargeted therapyTargeted therapy0302 clinical medicineCancer-Associated FibroblastsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor-Associated MacrophagesTumor MicroenvironmentPharmacology (medical)HypoxiaTOR Serine-Threonine KinasesSmall moleculesChemotherapy ; Hypoxia ; Inflammation ; Microenvironment ; Multidrug resistance ; Small molecules ; Targeted therapy.Drug Resistance Multiple3. Good healthDNA DemethylationGene Expression Regulation NeoplasticInfectious DiseasesOncology030220 oncology & carcinogenesisInflammation MediatorsEpithelial-Mesenchymal TransitionStromal cellMicroenvironmentBiologyProinflammatory cytokine03 medical and health sciencesCell Line TumormedicineAnimalsHumansChemotherapyEpithelial–mesenchymal transitionPharmacologyInflammationTumor microenvironmentCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseHistone Deacetylase InhibitorsMultiple drug resistanceDisease Models Animal030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer research
researchProduct

Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemi…

2016

Abstract Background Multidrug resistance (MDR) and drug transporter P-glycoprotein (P-gp) represent major obstacles in cancer chemotherapy. We investigated 19 synthetic curcumin derivatives in drug-sensitive acute lymphoblastic CCRF–CEM leukemia cells and their multidrug-resistant P-gp-overexpressing subline, CEM/ADR5000. Material and methods Cytotoxicity was tested by resazurin assays. Doxorubicin uptake was assessed by flow cytometry. Binding modes of compounds to P-gp were analyzed by molecular docking. Chemical features responsible for bioactivity were studied by quantitative structure activity relationship (QSAR) analyses. A 7-descriptor QSAR model was correlated with doxorubicin uptak…

Models Molecular0301 basic medicineCurcuminCell SurvivalT cellQuantitative Structure-Activity RelationshipAntineoplastic AgentsPharmacologyPrecursor T-Cell Lymphoblastic Leukemia-LymphomaToxicologyFlow cytometry03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansDoxorubicinATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityP-glycoproteinPharmacologybiologymedicine.diagnostic_testChemistrymedicine.diseaseDrug Resistance MultipleMultiple drug resistanceLeukemia030104 developmental biologymedicine.anatomical_structureDoxorubicinDrug Resistance NeoplasmCell culture030220 oncology & carcinogenesisbiology.proteinmedicine.drugToxicology and Applied Pharmacology
researchProduct

Potential multidrug resistance genePOHL: An ecologically relevant indicator in marine sponges

2001

Sponges are sessile filter feeders found in all aquatic habitats from the tropics to the arctic. Against potential environmental hazards, they are provided with efficient defense systems, e.g., protecting chaperones and/or the P-170/multidrug resistance pump system. Here we report on a further multidrug resistance pathway that is related to the pad one homologue (POH1) mechanism recently identified in humans. It is suggested that proteolysis is involved in the inactivation of xenobiotics by the POH1 system. Two cDNAs were cloned, one from the demosponge Geodia cydoniumand a second from the hexactinellid sponge Aphrocallistes vastus. The cDNA from G. cydonium, termed GCPOHL, encodes a deduce…

Health Toxicology and MutagenesisSaccharomyces cerevisiaeBiologybiology.organism_classificationMultiple drug resistanceSpongeBiochemistryComplementary DNABotanyGene expressionEnvironmental ChemistryChemosensitizing agentGeodiaGeneEnvironmental Toxicology and Chemistry
researchProduct